We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Read MoreHide Full Article
Key Takeaways
Zoetis' Cytopoint Plus receives a USDA license, delivering 75 days of relief from allergic itch in dogs.
The IL-31-targeting therapy offers a dosing interval about 1.5 times as long as existing mAb options.
Cytopoint Plus expands Zoetis' dermatology portfolio alongside Cytopoint, Apoquel and Apoquel Chewable.
Zoetis (ZTS - Free Report) announced that the U.S. Department of Agriculture (USDA) has licensed Cytopoint Plus, its next-generation monoclonal antibody (mAb) therapy for treating allergic dermatitis in dogs. The veterinarian-administered injection provides 75 days of relief from allergic itch, representing the longest treatment interval among USDA-licensed mAbs for the condition. The license adds a longer-duration option to ZTS’ canine dermatology franchise and expands its range of treatments for managing chronic itch in dogs.
Allergic dermatitis is a common skin condition triggered by factors such as flea bites, pollen, dust mites and food allergens. Affected dogs may experience persistent scratching, paw licking and skin irritation, with chronic symptoms potentially disrupting sleep and behavior. The condition represents a significant reason for veterinary visits, highlighting the need for therapies that offer durable symptom control. Research cited by Zoetis estimates that 15-20% of itchy dogs are diagnosed with allergic dermatitis. Because itching can also stem from infections or parasites, proper veterinary diagnosis remains important before selecting treatment.
ZTS’ Cytopoint Plus Extends Relief With a 75-Day Dosing Interval
Cytopoint Plus works by targeting and neutralizing interleukin-31 (IL-31), a protein involved in transmitting itch signals in dogs with allergic dermatitis. According to Zoetis, the therapy starts relieving itch within one day and maintains its effect for 75 days, or approximately 10.7 weeks. Administered subcutaneously by a veterinary professional every 75 days as needed, it provides an alternative for dogs requiring sustained control without frequent treatment appointments.
Year to date, Zoetis shares have plunged 34.4% compared with the industry’s 0.4% decline.
Image Source: Zacks Investment Research
The extended dosing schedule is a key differentiator. According to Zoetis, Cytopoint Plus offers a dosing interval approximately 1.5 times that of existing mAb options, potentially reducing the number of clinic visits needed over a year. This could help address missed appointments and gaps in treatment that may contribute to flare-ups. Fewer visits may also ease scheduling demands on pet owners and lessen stress for dogs uncomfortable with frequent trips to the veterinarian.
In studies supporting approval, Cytopoint Plus demonstrated efficacy through day 75, with reductions in itch scores versus controls observed through day 90 in some dogs. Zoetis also reported a safety profile similar to that of its established Cytopoint therapy. These findings support its potential role in long-term allergic dermatitis management, although veterinarians will need to assess each dog's condition and treatment response when determining a suitable dosing schedule.
How Cytopoint Plus Complements ZTS' Canine Dermatology Portfolio
The license strengthens a Zoetis dermatology portfolio that already includes Cytopoint, Apoquel and Apoquel Chewable. Like the new product, Cytopoint is an injectable mAb targeting IL-31, but its treatment interval is four to eight weeks. Cytopoint Plus thus extends the duration of relief available through this mechanism, rather than introducing an entirely different therapeutic target. The two injectable options can help veterinarians align treatment frequency with a dog's needs and its owner's ability to attend follow-up visits.
Meanwhile, Apoquel and Apoquel Chewable contain oclacitinib and offer oral treatment options for canine allergic itch. The chewable formulation provides an alternative to tablets, while the broader Apoquel franchise complements the company's injectable biologics. With treatments spanning oral formulations and veterinarian-administered injections, Zoetis can address differing preferences for administration and duration. Oral options also accommodate pet owners who prefer administering treatment at home rather than scheduling injections at a clinic. This range may be particularly useful in a condition where ongoing symptom management often requires an individualized approach.
Cytopoint Plus gives Zoetis another differentiated offering in an established therapeutic category. Its longer dosing interval may appeal to veterinarians seeking to simplify chronic care and to pet owners balancing treatment convenience with cost. However, the USDA license alone does not establish the pace of adoption or its eventual sales contribution. Market uptake will depend on factors such as pricing, access, veterinary recommendations and how the product performs in routine practice. The license comes amid competitive pressures in Zoetis' companion-animal business, particularly in dermatology, making portfolio differentiation increasingly relevant.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have climbed 72.3% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have lost 28% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 44 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 8 cents. ADPT’s shares have surged 84.3% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.
View the Zacks #1 Rank List
Image: Shutterstock
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Key Takeaways
Zoetis (ZTS - Free Report) announced that the U.S. Department of Agriculture (USDA) has licensed Cytopoint Plus, its next-generation monoclonal antibody (mAb) therapy for treating allergic dermatitis in dogs. The veterinarian-administered injection provides 75 days of relief from allergic itch, representing the longest treatment interval among USDA-licensed mAbs for the condition. The license adds a longer-duration option to ZTS’ canine dermatology franchise and expands its range of treatments for managing chronic itch in dogs.
Allergic dermatitis is a common skin condition triggered by factors such as flea bites, pollen, dust mites and food allergens. Affected dogs may experience persistent scratching, paw licking and skin irritation, with chronic symptoms potentially disrupting sleep and behavior. The condition represents a significant reason for veterinary visits, highlighting the need for therapies that offer durable symptom control. Research cited by Zoetis estimates that 15-20% of itchy dogs are diagnosed with allergic dermatitis. Because itching can also stem from infections or parasites, proper veterinary diagnosis remains important before selecting treatment.
ZTS’ Cytopoint Plus Extends Relief With a 75-Day Dosing Interval
Cytopoint Plus works by targeting and neutralizing interleukin-31 (IL-31), a protein involved in transmitting itch signals in dogs with allergic dermatitis. According to Zoetis, the therapy starts relieving itch within one day and maintains its effect for 75 days, or approximately 10.7 weeks. Administered subcutaneously by a veterinary professional every 75 days as needed, it provides an alternative for dogs requiring sustained control without frequent treatment appointments.
Year to date, Zoetis shares have plunged 34.4% compared with the industry’s 0.4% decline.
Image Source: Zacks Investment Research
The extended dosing schedule is a key differentiator. According to Zoetis, Cytopoint Plus offers a dosing interval approximately 1.5 times that of existing mAb options, potentially reducing the number of clinic visits needed over a year. This could help address missed appointments and gaps in treatment that may contribute to flare-ups. Fewer visits may also ease scheduling demands on pet owners and lessen stress for dogs uncomfortable with frequent trips to the veterinarian.
In studies supporting approval, Cytopoint Plus demonstrated efficacy through day 75, with reductions in itch scores versus controls observed through day 90 in some dogs. Zoetis also reported a safety profile similar to that of its established Cytopoint therapy. These findings support its potential role in long-term allergic dermatitis management, although veterinarians will need to assess each dog's condition and treatment response when determining a suitable dosing schedule.
How Cytopoint Plus Complements ZTS' Canine Dermatology Portfolio
The license strengthens a Zoetis dermatology portfolio that already includes Cytopoint, Apoquel and Apoquel Chewable. Like the new product, Cytopoint is an injectable mAb targeting IL-31, but its treatment interval is four to eight weeks. Cytopoint Plus thus extends the duration of relief available through this mechanism, rather than introducing an entirely different therapeutic target. The two injectable options can help veterinarians align treatment frequency with a dog's needs and its owner's ability to attend follow-up visits.
Meanwhile, Apoquel and Apoquel Chewable contain oclacitinib and offer oral treatment options for canine allergic itch. The chewable formulation provides an alternative to tablets, while the broader Apoquel franchise complements the company's injectable biologics. With treatments spanning oral formulations and veterinarian-administered injections, Zoetis can address differing preferences for administration and duration. Oral options also accommodate pet owners who prefer administering treatment at home rather than scheduling injections at a clinic. This range may be particularly useful in a condition where ongoing symptom management often requires an individualized approach.
Cytopoint Plus gives Zoetis another differentiated offering in an established therapeutic category. Its longer dosing interval may appeal to veterinarians seeking to simplify chronic care and to pet owners balancing treatment convenience with cost. However, the USDA license alone does not establish the pace of adoption or its eventual sales contribution. Market uptake will depend on factors such as pricing, access, veterinary recommendations and how the product performs in routine practice. The license comes amid competitive pressures in Zoetis' companion-animal business, particularly in dermatology, making portfolio differentiation increasingly relevant.
Zoetis Inc. Price and Consensus
Zoetis Inc. price-consensus-chart | Zoetis Inc. Quote
ZTS’ Zacks Rank & Stocks to Consider
Zoetis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) . AMRX sports a Zacks Rank #1 (Strong Buy), while ACIU and ADPT carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have climbed 72.3% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have lost 28% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 44 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 8 cents. ADPT’s shares have surged 84.3% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.